glp 1 agonist history Discovery of GLP-1–Based Drugs for the Treatment of Obesity History of GLP-1 Medications -
Description
doi: 10.4158/EP11290.OR
Current data suggest that the oral formulation leads to clinically meaningful weight loss, but on average, it appears less effective than higher doses of high-efficacy injectable GLP-1 therapies, says Jaime Almandoz, MD, medical director of UT Southwestern Medical Centers weight wellness program
The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
Reddys Laboratories, and Lupin are already working on GLP-1-based therapies, preparing for increased demand once patents expire in 2026 in various global markets
The weight loss numbers are more modest
Circ Res 116(9):15091526
